Shattuck Labs, Inc.
For the period ended Jun 30, 2026. Filed Aug 11, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 11, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Other Information
On June 12, 2026, Dr. Neil Gibson, amember of the Company's board of directors, adopted a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act (a “10b5-1 Plan”). Dr. Gibson’s 10b5-1 Plan provides for the potential sale of up to 71,083 shares of the Company’s common stock and will expire on the earlier of February 26, 2027 or the date when all shares under Dr. Gibson’s 10b5-1 Plan are sold, subject to certain conditions.
Other than as described above, during the three months ended June 30, 2026, none of our directors or Section 16 officers (as defined in Rule 16a-1(f) under the Exchange Act)adopted orterminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.